Here are the DEF 14A proxy statements from Sarepta Therapeutics,, Inc. (SRPT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SRPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRPT filings page.
Sarepta Therapeutics is asking stockholders to vote at its June 4, 2026 virtual annual meeting on five key items. Investors are asked to elect five Class I directors to serve until 2028, approve on an advisory basis 2025 executive pay, and ratify KPMG LLP as auditor for 2026.
The company also seeks approval of a new 2026 Equity Incentive Plan covering 6,740,000 shares and a 2026 Employee Stock Purchase Plan covering 1,500,000 shares. The proxy links these equity programs to retaining and motivating key talent during a planned CEO transition, as the current chief executive intends to retire by the end of 2026 or upon appointment of a successor.